ClinicalTrials.gg
CompletedNCT05031624Updated Jan 21, 2022

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

A Phase 1 interventional study of CDX-0159 and Normal saline in Healthy Subjects, sponsored by Celldex Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.

Read the detailed description

CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is expressed on mast cells.

The study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 administered subcutaneously in healthy subjects.

02

Conditions studied

  • Healthy Subjects

Keywords

  • CDX0159-05
03

In context

Lead sponsor

Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • An signed and dated by the subject.
  • Healthy volunteer aged 18-55.
  • In generally good health and without significant medical conditions based on physical exam, , and laboratory test results.
  • (BMI) ≥ 18.5 kg/m2 to ≤ 35 kg/m2
  • No medication other than mild analgesics, vitamins and mineral supplements or, oral .
  • Both males and females of child bearing potential must agree to use a medically accepted contraceptive regimen during study and up to 150 days afterwards.
  • Not a current smoker, vaper, or regular user of any nicotine or cannabinoid containing products
  • Willing to follow all study rules

Key Exclusion Criteria:

  • Women who are pregnant or nursing
  • History of anaphylaxis or systemic reactions to food or other triggers
  • disorders requiring more than topical medication
  • Vaccination with within 4 months prior to screening visit (subjects must agree to avoid live vaccination during the study and 4 months after).
  • Positive urine test for alcohol and drugs of abuse.

Other Protocol defined inclusion and exclusion criteria could apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CDX-0159

    Subjects will receive a single dose of CDX-0159

    Drug: CDX-0159

  • Placebo comparator
    Normal Saline

    Subjects will receive a single dose of normal saline

    Drug: Normal saline

Interventions

  • Single subcutaneous dose of one of four dosages of CDX-0159

  • DrugNormal saline

    Single subcutaneous dose of normal saline

06

What researchers measure

Primary outcomes

  1. Safety as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials

    Safety of single, ascending doses of CDX-0159 as determined by percentage of participants with adverse events as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials

    Time frame: Day 1 to Day 85

Secondary outcomes

  1. CDX-0159 serum evaluations over time

    CDX-0159 serum concentrations will be measured at specified visits

    Time frame: Day 1 to Day 85

  2. Serum tryptase levels over time

    The effect of CDX-0159 on serum tryptase levels

    Time frame: Day 1 to Day 85

  3. Plasma levels over time

    The effect of CDX-0159 on stem cell factor levels

    Time frame: Day 1 to Day 85

  4. Measurement of Anti-drug Antibody development over time

    Patients will be monitored for the development of anti-drug antibodies.

    Time frame: Day 1 to Day 85

07

Study locations

1 site
  • Celerion, Inc
    Lincoln, Nebraska 68502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jan 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Sep 2, 2021
StartActual
Aug 30, 2021
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05031624
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Aug 30, 2021
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Last update
Jan 21, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion